Hand, Foot, and Mouth Disease in Hunan Province, China, 2009-2014: Epidemiology and Death Risk Factors

Kai-Wei Luo *, Li-Dong Gao, Shi-Xiong Hu, Hong Zhang, Zhi-Hong Deng, Wei Huang, Qian-Lai Sun, Fan Zhang, Si-Yu Zhang, Yu Chen

Hunan Provincial Center for Disease Control and Prevention, Hunan, China

*hncdclkw@163.com

Abstract

Hand, foot, and mouth disease (HFMD) is an arising public health problem in Asia, including China. Epidemiological data is necessary to enable judicious public health responses and interventions. We analyzed the epidemiological and laboratory data of 759,301 HFMD cases reported to the Hunan Provincial Center for Disease Control and Prevention from 1 January 2009 to 31 December 2014. Univariate and multivariable conditional logistic regression analyses were used to identify risk factors of fatality in HFMD. The incidence of HFMD was highest among children aged 1–3 years, compared with other age groups. Of the total HFMD cases, 7,222 (0.95%) were considered severe and 338 (0.04%) were fatal. Enterovirus-A71 was the major cause of severe and fatal cases (65.75% and 88.78%, respectively). For severe cases, the median time from symptom onset to diagnosis was 0.5 days (interquartile range [IQR] 0–1.5 days); the median time from diagnosis to severe illness was 2 days (IQR 1–3 days). For fatal cases, the median time from symptom onset to diagnosis was 0.5 days (IQR 0–1.5 days); the median time from diagnosis to death was 1.5 days (IQR 0.5–2.5 days). In multivariable analysis, the abuse of antibiotic, glucocorticoid and pyrazolone in village clinics at basic medical institutions were identified as independent risk factors for HFMD fatal cases. In conclusion, our results suggest that the future direction to control and respond to HFMD is intensive surveillance of enterovirus-A71 and improving the ability to diagnose disease and treat patients, especially in basic medical institutions.

Introduction

Hand, foot, and mouth disease (HFMD) is an illness of infants and children under 5 years old that is characterized by mouth ulcers and vesicles on the hands, feet, or hips [1]. The infection is usually self-limiting and mild. However, some patients rapidly develop neurological and systemic complications that can be fatal [2]. HFMD is caused by various enteroviruses (EV), most commonly enterovirus 71 (EV-A71) or coxackie virus A16 (CV-A16) [3–5]. EV-A71 is often associated with major HFMD outbreaks throughout the world [6–9].
In response to the increasing number of HFMD cases in China, especially those that are severe or fatal, the Chinese government established a network-based national surveillance system for HFMD in May 2008. Through this surveillance system, individual cases are reported to the local county- or city-level Center for Disease Control (CDC). The provincial CDC then reviews all case reports, including epidemiological and laboratory data.

In Hunan Province, because of delays in laboratory construction and the network, surveillance data was not reliable until January 2009. To enable the design of better control measures, we conducted the present study of the epidemiological, pathogenic, and clinical characteristics of HFMD in Hunan Province, based on surveillance data collected from January 2009 to December 2014.

Methods

Ethics statement

In May 2008, HFMD was added to the list of notifiable diseases in China. According to China’s law on the prevention and treatment of infectious diseases, for the purposes of public health surveillance and response, a diagnosis of a notifiable disease allows the collection of personal information for individual cases. The National Health and Family Planning Commission of China decreed that individual data for all notifiable diseases, including HFMD, is part of an ongoing public health response and thus is exempt from institutional review board assessment. The China CDC and Hunan CDC have strict regulations on the protection of patients’ privacy. The Center for Public Health Surveillance and Information Services (CPHSIS) at the China CDC is responsible for the management of all disease surveillance data. The CPHSIS anonymizes individual HFMD data by deleting personal identifiers, including patient name, parent name, home address, and telephone number. The authors were given access to the surveillance data for the purposes of research. The co-authors of this article did not participate in de-identifying the data and do not have the personal identifiers of the HFMD cases.

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation, and with the Helsinki Declaration of 1975, as revised in 2008.

Demographic information of Hunan Province

Hunan Province is located in South Central China, and has a significant HFMD burden. The incidence and mortality rates of HFMD have both ranked among the top 5 diseases in China since 2009 [10].

Hunan Province is divided into 14 prefectures and has an area of 211,800 square kilometers (comparable to the area of Romania) and a population of 71 million. The per capita gross regional product is 33,480 Chinese Yuan (CNY, ~USD $5,444), which is the middle economic level in China [11].

Surveillance system

Cases of HFMD are reported via a web-based public health surveillance system. Data are sent immediately to the national database. CDC officers at different levels are able to access the information within their jurisdiction as soon as the information becomes available.

From January 2009 to December 2014, the surveillance system included a minimum of 5 mild cases and all severe and fatal cases (defined below) per prefecture per month.
Diagnostic criteria

A suspected case of HFMD (i.e., clinically diagnosed) was defined as a patient with a papular or vesicular rash on hands, feet, mouth, or hips, with or without fever. A laboratory-confirmed case was defined as a suspected case with laboratory evidence of enterovirus infection (EV-A71, CV-A16, or other EV detected by RT-PCR, real-time PCR or virus isolation) [12, 13].

The cases were classified as mild, severe, or fatal based on the diagnostic criteria established in the Hand, Foot and Mouth Disease Control and Prevention Guide (2009), and in the Hand, Foot and Mouth Disease Treatment Guidelines (2010), published by the Ministry of Health of China [14, 15]. Briefly, the standard diagnosis of a mild case of HFMD includes the presence of a skin rash on the hands, feet, mouth, or hips, with or without fever. A severe case of HFMD was determined according to additional neurological, cardiogenic, or pulmonary symptoms. A fatal case was identified when HFMD was confirmed as the cause of death.

Pathogen serotype

The CDCs in cities and counties collected and analyzed all case specimens (feces, throat swabs, anal swabs, ulcer fluid, and cerebrospinal fluid) through the standard quality control procedures of the Hunan provincial CDC. In the laboratory, RNA extraction was conducted using a commercial viral nucleic acid extraction kit (Geneaid Biotech, New Taipei City, Taiwan); real-time PCR was performed using a commercially available kit (Bioperfectus, Jiangsu, China), both in accordance with the manufacturer’s instructions. The specifications for specimen collection and real-time RT-PCR were outlined and performed in accordance with the requirements detailed in the chapter on HFMD specimen collection and testing technology in Hand, Foot and Mouth Disease Control and Prevention Guide (2009) [14].

Data analysis

We included all HFMD cases from 1 January 2009 to 31 December 2014 in the analysis. We determined the rates of case-severity, case-fatality, and case-fatality among severe cases, as follows. The case-severity rate was the number of severe cases divided by the sum of suspected and confirmed cases. The case-fatality rate was the number of deaths divided by the sum of suspected and confirmed cases. The severe case-fatality rate was the number of deaths divided by the sum of severe cases and deaths.

In addition, we analyzed the times from symptom onset to diagnosis, from diagnosis to severity, and from severity to death. In laboratory-confirmed cases, we calculated the proportions of different serotypes.

Case-control survey investigation

To find the risk factors of fatality in HFMD, 177 fatal cases for which detailed epidemiological data was available were included as the death group in univariate and multivariable conditional logistic regression analyses. As a control group, 2 severe cases were selected for each single fatal case. The questionnaire could be found in S1 Table.

The death and control groups were matched by gender and symptom onset dates (≤ 14 days apart). The symptom onset date was defined as the date when the patient started to show symptoms of papular or vesicular rash on the hands, feet, mouth, or hips, with or without fever. Univariate conditional logistic regression analyses were used to analyze 22 variables that previous studies had indicated may be associated with fatality in HFMD [16–19]. Those variables that were identified in the present study were then included as candidates in the
multivariable conditional logistic regression model, by stepwise selection. SPSS 17.0 software was used to conduct all statistical analyses. A two-sided \( P < 0.05 \) was considered significant.

**Results**

A total of 759,301 cases of HFMD were reported to the surveillance system during the years 2009 to 2014, of which 7,222 (0.9%) were severe cases and 338 (0.1%) were fatal (Table 1). There were 43,111 (5.68%) laboratory-confirmed cases. Of all 759,301 cases, 476,156 (62.7%) were male and 283,145 (37.3%) were female, and the overall male-to-female ratio was 1.68:1. Most of the children affected were cared for at home, but also there were many children affected at kindergartens.

The incidence rates of HFMD varied greatly by age, with the greatest number of children aged 6 months to 3 years (Table 2). The incidence rate was very low in infants aged younger than 6 months or children over 6 years old. HFMD activity tended to peak semiannually, including a major peak in spring and early summer and then a minor peak in autumn (Fig 1). The major peak from April to July included 53.27% of all reported cases, while the smaller peak between September and November included 14.01%. Notably, these semiannual peaks were more obvious in mid-eastern cities such as Yueyang City than in western cities such as Zhangjiajie City. The number of cases between 2009 and 2014 increased in even-numbered years (i.e., 2010, 2012, and 2014); the average number of cases in even-numbered years was twice that of odd-numbered years. Although the overall incidence of HFMD increased during the 6 years (from 5.42 million to 31.83 million) the fatality rate dropped from 0.05% to 0.02%, and the severe case-fatality rate dropped from 1.89% to 0.22% (Fig 2).

Table 1. Case distribution and demographic characteristics of reported HFMD cases in Hunan Province, China, 2009–2014.

| Age, y | 2009  | 2010  | 2011  | 2012  | 2013  | 2014  | Total |
|--------|-------|-------|-------|-------|-------|-------|-------|
| <0.5   | 321.36| 1504.14| 604.8 | 1805.61| 922.56 | 1504.89| 759,301|
| 0.5–0.9| 10029.45| 35801.42| 30548.81| 44095.71| 37091.74 | 55894.03| 123,145|
| 1–3   | 22,717 (65.6) | 68,873 (61.5) | 68,091 (66.6) | 130,883 (69.1) | 70,567 (65.3) | 139,419 (65.5) | 500,550 (65.9) |
| 4–5   | 2,229 (6.4) | 7,523 (6.7) | 5,827 (5.7) | 10,726 (5.7) | 4,975 (4.6) | 14,646 (6.9) | 45,926 (6.1) |
| ≥6    | 2,172 (6.3) | 8,521 (7.6) | 5,588 (5.4) | 13,240 (7.0) | 4,769 (4.4) | 13,846 (6.5) | 48,136 (6.3) |

Table 2. The age-specific incidence rate (per million) in Hunan Province, China, 2009–2014.

| Age, y | 2009  | 2010  | 2011  | 2012  | 2013  | 2014  | Total |
|--------|-------|-------|-------|-------|-------|-------|-------|
| <0.5   | 321.36| 1504.14| 604.8 | 1805.61| 922.56 | 1504.89| 759,301|
| 0.5–0.9| 10029.45| 35801.42| 30548.81| 44095.71| 37091.74 | 55894.03| 123,145|
| 1–3   | 22,717 (65.6) | 68,873 (61.5) | 68,091 (66.6) | 130,883 (69.1) | 70,567 (65.3) | 139,419 (65.5) | 500,550 (65.9) |
| 4–5   | 2,229 (6.4) | 7,523 (6.7) | 5,827 (5.7) | 10,726 (5.7) | 4,975 (4.6) | 14,646 (6.9) | 45,926 (6.1) |
| ≥6    | 2,172 (6.3) | 8,521 (7.6) | 5,588 (5.4) | 13,240 (7.0) | 4,769 (4.4) | 13,846 (6.5) | 48,136 (6.3) |
A total of 43,111 cases were tested in the laboratory, 36,007 mild, 6,871 severe, and 233 fatal cases, respectively. Among the laboratory-tested cases, 62.59% (26,985 cases) were confirmed HFMD. Enteroviruses (e.g., EV-A71, CV-A16, and untyped enteroviruses) were identified as the cause in ~75% of the mild cases. In particular, in mild cases untyped enteroviruses were the cause in 43.35% and EV-A71 were the cause in 31.85%. On the other hand, EV-A71 was the major cause in 65.75% and 88.78% of severe and fatal cases, respectively (Fig 3). Notably, EV-A71 predominated in 2010 and 2012 when the most serious epidemics were recorded. However, when other enteroviruses became more dominant than EV-A71 in 2009, 2013, and 2014, the case-severity rates were much lower compared to other years.

The median time of severe cases from symptom onset to diagnosis was 0.5 days (interquartile range [IQR] 0–1.5 days), while the median time from diagnosis to disease severity was 2 days (IQR 1–3 days; Fig 4). For fatal cases, the median time from symptom onset to diagnosis was the same as that of severe cases, but the time from diagnosis to severe illness was 1.5 days (IQR 0.5–2.5 days).

The univariate conditional logistic regression analysis showed no significant difference between the death and control (severe) groups with regard to the following: age; occupation;
birth order of patient; gestational weeks of the mother; delivery mode; birth weight; pattern of infant feeding; style of child-care; educational level of the people caring for the children; or histories of obstetric labor complications, congenital malformations, congenital heart disease, or drug or food allergies. On the other hand, eight variables were significantly associated with fatal cases: reside in city areas, first visit in higher level hospitals, correct diagnosis when first visit, shorter time between symptom onset to first visit, shorter time between symptom onset to county hospital were protective factors, while using antibiotic in village clinics, using glucocorticoid in village clinic, using pyrazolone in therapeutic process were risk factors (Table 3). Subsequently these eight variables were entered in multivariable conditional logistic regressions. All factors remained significantly associated with fatal cases except for correct diagnosis when first visit. (Table 4).
Discussion

In this study, we investigated more than 750,000 cases of HFMD reported from the national enhanced surveillance system from 2009 to 2014. This report provides the first comprehensive

Table 3. Distribution of case and control groups and univariate conditional logistic regression model.

| Subjects, n | Deaths group | Control group | OR (95% CI) | P  |
|-------------|--------------|---------------|-------------|----|
| Subjects, n | 177          | 354           |             |    |
| Age, y       |              |               |             |    |
| <1          | 21 (11.9%)   | 13 (3.7%)     | 2.019 (0.457–8.920) | 0.354|
| 1–3         | 146 (82.5%)  | 320 (90.4%)   | 0.570 (0.151–2.155) | 0.408|
| 4–5         | 6 (3.4%)     | 16 (4.5%)     | 0.469 (0.093–2.357) | 0.358|
| >6          | 4 (2.3%)     | 5 (1.4%)      | Reference    | —  |
| Profession type |          |               |             |    |
| Isolated children | 159 (89.8%) | 298 (84.2%)   | 1.067 (0.263–4.324) | 0.927|
| Childcare   | 15 (8.5%)    | 50 (14.1%)    | 0.600 (0.134–2.692) | 0.505|
| Student     | 3 (1.7%)     | 6 (1.7%)      | Reference    | —  |
| Residence   |              |               |             |    |
| Rural       | 140 (79.1)   | 227 (64.1%)   | 3.152 (1.824–5.449) | <0.0001|
| Rural-urban fringe | 19 (10.7%) | 35 (9.9%)     | 2.775 (1.307–5.892) | 0.008|
| Urban       | 18 (10.2%)   | 92 (26.0%)    | Reference    | —  |
| First-visit hospital level |          |               |             |    |
| Village     | 88 (49.7%)   | 74 (20.9%)    | 5.203 (2.785–9.719) | <0.0001|
| Township    | 40 (22.6%)   | 113 (31.9%)   | 1.549 (0.807–2.972) | 0.189|
| County      | 33 (18.6%)   | 97 (27.4%)    | 1.488 (0.760–2.913) | 0.246|
| City        | 16 (9.0%)    | 70 (19.8%)    | Reference    | —  |
| Correct diagnosis upon first visit |          |               |             |    |
| Y           | 44 (24.9%)   | 149 (42.1%)   | 2.197 (1.471–3.280) | <0.0001|
| N           | 133 (75.1)   | 205 (57.9%)   | Reference    | —  |
| Time from onset to first visit, d |          |               |             |    |
| 0           | 24 (13.6%)   | 102 (28.8%)   | 0.118 (0.067–0.206) |    |
| 1–2         | 55 (31.1%)   | 203 (57.3%)   | 0.135 (0.086–0.213) | <0.0001|
| ≥3          | 98 (55.4%)   | 49 (13.8%)    | Reference    | —  |
| a Time from onset to county hospital, d |          |               |             |    |
| 0           | 25 (16.23%)  | 96 (28.74%)   | 0.187 (0.109–0.319) | <0.0001|
| 1–2         | 30 (19.48%)  | 167 (50.00%)  | 0.129 (0.079–0.211) | <0.0001|
| ≥3          | 99 (64.29%)  | 71 (21.26%)   | Reference    | —  |
| Antibiotic given at village clinic |          |               |             |    |
| Y           | 64 (36.2%)   | 58 (16.4%)    | 2.890 (1.906–4.382) | <0.0001|
| N           | 113 (63.8%)  | 296 (83.6%)   | Reference    | —  |
| Glucocorticoid given at village clinic |          |               |             |    |
| Y           | 11 (6.2%)    | 4 (1.1%)      | 5.798 (1.819–18.481) | 0.003|
| N           | 166 (93.8%)  | 350 (98.9%)   | Reference    | —  |
| Pyrazolone during therapy |          |               |             |    |
| Y           | 50 (28.2%)   | 25 (7.1%)     | 5.181 (3.074–8.732) | <0.0001|
| N           | 127 (71.8%)  | 329 (92.9%)   | Reference    | —  |

a Some cases did not went the county hospitals.
understanding of the epidemiological burden of HFMD in Hunan Province, a disease that causes illness and death among children less than 5 years old [10, 20–22]. Hunan Province lies in the middle of China with an economy that is mid-level. The province also ranks among the first for both incidence and mortality rates of HFMD. As in many other provinces in China, the incidence rate of HFMD infections increased from 2009 to 2014, reflecting both the rapid increase of HFMD in China and the improvement in HFMD case reporting and surveillance [23, 24]. However, despite the increase in incidence the case-fatality rate dropped steadily, which reflects improvement in the treatment of severe cases in recent years.

As in other southern provinces in China, HFMD in Hunan had semiannual peaks of activity, including a major peak in spring and summer, and a smaller peak in autumn [25]. However, this pattern changed by latitude, and only one peak in summer was detected in provinces in the north [26]. A reasonable explanation of this phenomenon could be the influence of temperature and humidity on the activity of enteroviruses. The high incidence in every other year was likely a result in periodic depletion and replenishment of the susceptible population. Climate and geographic factors may influence the periodicity of incidence as well.

The age profile of HFMD was consistent with reports from other provinces in China and other countries [27, 28]. The young-age characteristic of HFMD infection suggests that enteroviruses are highly transmissible, while the relatively low incidence rate in infants younger than 6 months was most likely due to protection by maternal antibodies. The high incidence rate in children aged 0.5–3 years (mostly children living at home) and 4–5 years old (mostly

| Table 4. Adjusted odds ratio (OR) and 95% confidence interval (CI) derived from multiple conditional logistic regression model. |
|-------------------------------------------------|-------------------|-----------------|
| Residence                                       | OR (95% CI)       | P               |
| Rural                                           | 3.205 (1.445–7.112) | 0.004 |
| Rural-urban fringe                              | 3.313 (1.090–10.071) | 0.035 |
| Urban                                           | Reference         | —               |
| First-visit hospital level                      |                   |                 |
| Village                                         | 18.798 (7.880–44.844) | <0.0001 |
| Township                                        | 5.129 (2.102–12.515) | <0.0001 |
| County                                         | 2.974 (1.164–7.596) | 0.023 |
| City                                           | Reference         | —               |
| Time from onset to first visit, d               |                   |                 |
| 0                                              | 0.030 (0.011–0.077) | <0.0001 |
| 1–2                                            | 0.141 (0.069–0.288) | <0.0001 |
| ≥3                                             | Reference         | —               |
| a Time from onset to county hospital, d         |                   |                 |
| 0                                              | 0.032 (0.012–0.080) | <0.0001 |
| 1–2                                            | 0.067 (0.032–0.142) | <0.0001 |
| ≥3                                             | Reference         | —               |
| Antibiotic given at village clinic              |                   |                 |
| Y                                              | 21.116 (9.384–47.518) | <0.0001 |
| N                                              | Reference         | —               |
| Glucocorticoid given at village clinic          |                   |                 |
| Y                                              | 6.641 (1.087–40.565) | 0.04 |
| N                                              | Reference         | —               |
| Pyrazolone during therapy                       |                   |                 |
| Y                                              | 3.046 (1.202–7.715) | 0.019 |
| N                                              | Reference         | —               |

* Some cases did not went the county hospitals.

doi:10.1371/journal.pone.0167269.t004
children in kindergartens), suggests that these populations are key to preventing and controlling HFMD.

We also found that more boys were affected by HFMD than girls, and the gender distribution was similar to that observed in other Asian regions [29, 30]. This may indicate that boys are more susceptible to enterovirus infection. It is worth noting that the male-to-female ratio declined from 2.01 in 2009 to 1.53 in 2014. This trend needs further monitoring.

The data derived from surveillance and laboratory monitoring in Hunan showed that HFMD morbidity and mortality were associated with infections by EV-A71, CV-A16, and untyped enteroviruses. In particular, untyped enterovirus was the predominant cause of mild laboratory-confirmed cases, but EV-A71 predominated in severe and fatal cases. This may be because EV-A71 usually invades the nervous and respiratory systems and leads to acute neurologic and respiratory diseases such as paralysis, encephalitis, aseptic meningitis, and pneumoedema [31]. HFMD EV-A71-associated neurological syndrome has increased in many countries during the past 5 years, especially in the Asia-Pacific region [32, 33]. In general, since the predominant virus serotype varies each year, the periodicity of HFMD may be complicated by interference between causative enterovirus serotypes [32, 33]. A limitation of our study is that we did not test other enterovirus serotypes, such as CV-A6 or CV-A10, which are becoming more predominant in some provinces of southern China [34].

Fatalities due to HFMD are a huge burden to patients’ families and society, and doctors and the public health department want to know why some severe cases recover but others do not. Thus, we investigated risk factors that may differentiate clinical outcomes in severe cases, enable doctors to monitor and treat accordingly, and guide prevention and control measures by public health departments. The results showed that inappropriate utilization of glucocorticoids, pyrazolones, and antibiotics in village clinics were the risk factors of fatality—the outcomes of patients given these medications differed drastically from the control group.

Glucocorticoids, such as dexamethasone, are commonly used by rural practitioners in China to treat fever, and it is appropriate to use glucocorticoid to diminish inflammation in severe cases of HFMD. However, early use of glucocorticoid in mild cases caused by human EV-A71 has been found to worsen the disease [35,36]. Also, using antibiotics in village clinics was identified as a risk factor of HFMD fatality. A possible reason is that the combination of antibiotics, glucocorticoids, vitamins, and fluid therapy to treat fever is habitually abused in grassroots medical institutions in some villages of China. Thus, we suggest that antibiotics and glucocorticoids should be used with caution in grassroots medical institutions, especially in the early stages of illness.

In the present study, another risk factor of fatality was treatment with pyrazolone; this result is similar to studies reported previously [36, 37]. Pyrazolone derivatives (including aminopyrine, analginum, and phenylbutazone) have been banned and restricted in many developed countries for various adverse drug reactions [38]. However, pyrazolone derivatives are still used broadly in Chinese rural areas for its low price and powerful antipyretic effects. Therefore, we encourage the Hygiene Administrative Department to restrict the use of pyrazolone drugs, especially for children. Most rural patients first seek medical care in the village, followed by township, county, and then city hospitals. However, only hospitals at the county level and higher admit HFMD as severe cases, in accordance with national rules. Therefore, improvement of HFMD awareness and diagnostic measures at lower level hospitals is crucially important to rescue severe cases.

In conclusion, HFMD is an increasingly important public health problem in Hunan Province of China. EV-A71 infection results in severe and fatal cases. Preschool children are at highest risk of HFMD infection. It is important to avoid the injudicious use of drugs, especially antibiotics, in basic medical institutions. Taken together, future efforts to control and respond
to HFMD should focus on intensive surveillance of EV-A71, improving the ability to diagnose and treat illness, especially in basic medical institutions.

**Supporting Information**

S1 Table. The severe or death hand, foot, and mouth disease case questionnaire. (DOC)

**Acknowledgments**

The authors thank the individuals at the CDCs at Changsha, Xiangtan, Zhuzhou, Hengyang, Shaoyang, Yueyang, Changde, Zhangjiajie, Yiyang, Chenzhou, Yongzhou, Huaihua, Loudi, and Xiangxi autonomous region for collecting samples.

**Author Contributions**

Data curation: WH FZ YC K-WL.

Formal analysis: K-WL Z-HD Q-LS S-YZ.

Funding acquisition: L-DG K-WL.

Investigation: K-WL Q-LS S-YZ.

Methodology: K-WL L-DG S-XH HZ.

Project administration: L-DG S-XH.

Writing – original draft: K-WL.

Writing – review & editing: K-WL L-DG.

**References**

1. Lu B, Guo H, Lu H. Hand, foot, and mouth disease in mainland China. The Lancet Infectious Diseases 2014; 14(11): 1041.

2. He LY, Zhang GL, Yan SY, Liu Y, Zhao CS, Wang XL, et al. A double-blind comparative study of Chinese herbal medicine Jinlianqin Effervescent Tablets in combination with conventional therapy for the treatment of uncomplicated hand, foot, and mouth disease. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology 2014; 33(8): 1429–1437.

3. Kadurugamuwa JL, Shaheen E. Inactivation of human enterovirus 71 and coxsackie virus A16 and hand, foot, and mouth disease. American journal of infection control 2011; 39(9): 788–789. doi: 10.1016/j.ajic.2011.01.015 PMID: 21565426

4. Xu M, Su LY, Cao LF, Zhong HQ, Dong NN, Xu J. Enterovirus genotypes causing hand foot and mouth disease in Shanghai, China: a molecular epidemiological analysis. BMC infectious diseases 2013; 13: 489. doi: 10.1186/1471-2334-13-489 PMID: 24148902

5. Wong SS, Yip CC, Lau SK, Yuen KY. Human enterovirus 71 and hand, foot and mouth disease. Epidemiology and infection 2010; 138(8): 1071–1089. doi: 10.1017/S0950268809991555 PMID: 20056019

6. Hosoya M, Kawasaki Y, Sato M, Honzumi K, Kato A, Hiroshima T, et al. Genetic diversity of enterovirus 71 associated with hand, foot and mouth disease epidemics in Japan from 1983 to 2003. The Pediatric infectious disease journal 2006; 25(8): 691–694. doi: 10.1097/01.inf.0000227959.89339.c3 PMID: 16874167

7. Shimizu H, Utama A, Yoshii K, Yoshida H, Yoneyama T, Sinniah M, et al. Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997–1998. Japanese journal of infectious diseases 1999; 52(1): 12–15. PMID: 10808253

8. Ma E, Chan KC, Cheng P, Wong C, Chuang SK. The enterovirus 71 epidemic in 2008—public health implications for Hong Kong. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2010; 14(9): e775–780.
9. Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virology journal 2010; 7: 94. doi: 10.1186/1743-422X-7-94 PMID: 20459851

10. Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. The Lancet Infectious diseases 2014; 14(4): 308–318. doi: 10.1016/S1473-3099(13)70342-6 PMID: 24485991

11. National Bureau of Statistics of China. National census in China in 2014. http://www.stats.gov.cn/tjsj/ndsj/2014/indexeh.htm (accessed JAN 9, 2015).

12. Fan X, Jiang J, Liu Y, Huang X, Wang P, Liu L, et al. Detection of human enterovirus 71 and Coxsackievirus A16 in an outbreak of hand, foot, and mouth disease in Henan Province, China in 2009. Virus genes 2013; 46(1): 1–9. doi: 10.1007/s11262-012-0814-x PMID: 23080402

13. Gao LD, Hu SX, Zhang H, Luo KW, Liu YZ, Xu QH, et al. Correlation analysis of EV71 detection and case severity in hand, foot, and mouth disease in the Hunan Province of China. PloS one 2014; 9(6): e100003. doi: 10.1371/journal.pone.0100003 PMID: 24941257

14. The Ministry of Health of China. Guideline for HFMD public health response. 2009. http://www.chinacdc.cn/jkzt/crb/szkb/jszl_2275/200906/t20090612_24707.html (accessed Jan 9, 2013).

15. The Ministry of Health of China. Hand, Foot and Mouth Disease Treatment Guidelines (2010). http://www.nhfpc.gov.cn/yzygj/s3593g/201306/6d935c0f43cd4a1fb46f8f71acfb8e245.shtml (accessed Apr 20, 2010).

16. Li W, Teng G, Tong H, Jiao YM, Zhang T, Chen H, et al. Study on risk factors for severe hand, foot and mouth disease in China. PloS one 2014; 9(1): e87603. doi: 10.1371/journal.pone.0087603 PMID: 24489943

17. Wu X, Sun Y, Lin C, Jia L, Wu Q, Li X, et al. A case-control study to identify environmental risk factors for hand, foot, and mouth disease outbreaks in Beijing. Japanese journal of infectious diseases 2013; 57(4): 316–9. PMID: 23080402

18. Chen SM, Du JW, Jin YM, Qiu L, Du ZH, Li DD, et al. Risk Factors for Severe Hand-Foot-Mouth Disease in Children in Hainan, China, 2011–2012. Asia-Pacific journal of public health / Asia-Pacific Academic Consortium for Public Health 2015; 27(7): 715–722.

19. Pan J, Chen MW, Zhang XZ, Chen YL, LIU H, Shen W. High risk factors for severe hand, foot and mouth disease: a multicenter retrospective survey in Anhui Province China, 2008–2009. Indian journal of dermatology 2012; 57(4): 316–321. doi: 10.4103/0019-5154.97683 PMID: 22837575

20. Zheng S, Cao CX, Cheng JQ, Wu YS, Xie X, Xu M. Epidemiological features of hand-foot-and-mouth disease in Shenzhen, China from 2008 to 2010. Epidemiology and infection 2014; 142(8): 1751–1762. doi: 10.1017/S0950268813002586 PMID: 24139426

21. Gan ZK, Jin H, Li JX, Yao XJ, Zhou Y, Zhang XF, et al. Disease burden of enterovirus 71 in rural central China: A community-based survey. Human vaccines & immunotherapeutics 2015; 11(10): 2400–2405.

22. Zhou H, Guo SZ, Zhou H, Zhu YF, Zhang LJ, Zhang W. Clinical characteristics of hand, foot and mouth disease in Harbin and the prediction of severe cases. Chinese medical journal 2012; 125(7): 1261–1265. PMID: 22613598

23. Lu J, Zeng H, Zheng H, Yi L, Guo X, Liu L, et al. Hand, foot and mouth disease in Guangdong, China, in 2013: new trends in the continuing epidemic. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2014; 20(7): O442–445.

24. Yan Y, Guo J, Zhou JZ, Tang GP, Wang DM. Analysis on molecular epidemiological features of enterovirus type 71 in Guizhou Province, 2008–2011. Chinese journal of virology 2013; 29(2): 176–179. PMID: 23757849

25. Chen Z, Sun H, Yan Y, Wang Y, Zhu C, Zhou W, et al. Epidemiological profiles of hand, foot, and mouth disease, including meteorological factors, in Suzhou, China. Archives of virology 2015; 160(1): 315–321. doi: 10.1007/s00705-014-2294-x PMID: 25430907

26. Huang X, Wei H, Wu S, Du Y, Liu L, Su J, et al. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Henan, China, 2008–2013. Scientific reports 2015; 5: 8904. doi: 10.1038/srep08904 PMID: 25754970

27. Ang LW, Tay J, Phoon MC, Hsu JP, Cutter J, et al. Seroepidemiology of Coxsackievirus A6, Coxsackievirus A16, and Enterovirus 71 Infections among Children and Adolescents in Singapore, 2008–2010. PloS one 2015; 10(5): e0127999. doi: 10.1371/journal.pone.0127999 PMID: 26011735

28. Xie Z, Wang L, Yan Y, Hong R, Ou J, Huang W, et al. A cohort study on the characteristics of the recent epidemics on hand, foot and mouth disease, in Fujian province. Zhonghua liu xing bing xue za zhi 2014; 35(10): 1109–1114. PMID: 25567014
29. Nguyen NT, Pham HV, Hoang CQ, Nguyen TM, Nguyen LT, Phan HC, et al. Epidemiological and clinical characteristics of children who died from hand, foot and mouth disease in Vietnam, 2011. BMC infectious diseases 2014; 14: 341. doi: 10.1186/1471-2334-14-341 PMID: 24942066
30. Chatproeudprai S, Theanboonlers A, Korkong S, Thongmee C, Wananukul S, Poovorawan Y. Clinical and molecular characterization of hand-foot-and-mouth disease in Thailand, 2008–2009. Japanese journal of infectious diseases 2010; 63(4): 229–233. PMID: 20657060
31. Nadel S. Hand, foot, mouth, brainstem, and heart disease resulting from enterovirus 71. Critical care medicine 2013; 41(7): 1821–1822. doi: 10.1097/CCM.0b013e318291cb2d PMID: 23774351
32. Mauleekoonphairoj J, Vongpunsawad S, Puenpa J, Korkong S, Yong P. Complete genome sequence analysis of enterovirus 71 isolated from children with hand, foot, and mouth disease in Thailand, 2012–2014. Virus genes 2015; 51(2): 290–293. doi: 10.1007/s11262-015-1239-0 PMID: 26303899
33. Liu W, Wu SM, Xiong Y, Li TY, Wen Z, Yan MZ, et al. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China. PLoS one 2014; 9(4): e96051. doi: 10.1371/journal.pone.0096051 PMID: 24776922
34. Zha J, Ma Z. Epidemiological and genetic analysis concerning the coxsackievirus A6 related endemic outbreak of hand-foot-mouth disease in Taizhou, China, during 2013. Journal of medical virology 2015; 87(12): 2000–2008. doi: 10.1002/jmv.24272 PMID: 25989289
35. Hubiche T, Schuffenecker I, Boralevi F, Léauté-Labrèze C, Bornebusch L, Chiaverini C, et al. Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema. The Pediatric infectious disease journal 2014; 33(4): e92–98. doi: 10.1097/INF.0000000000000120 PMID: 24463804
36. Ma H, He F, Wan J, Jin D, Zhu L, Liu X, et al. Glucocorticoid and pyrazolone treatment of acute fever is a risk factor for critical and life-threatening human enterovirus 71 infection during an outbreak in China, 2008. The Pediatric infectious disease journal 2010; 29(6): 524–529. doi: 10.1097/INF.0b013e3181cdd178 PMID: 20104199
37. Mou J, Dawes M, Li Y, He Y, Ma H, Xie X, et al. Severe hand, foot and mouth disease in Shenzhen, South China: what matters most? Epidemiology and infection 2014; 142(4): 776–788. doi: 10.1017/S0950268813001453 PMID: 23809677
38. Czerniawska-Mysik G, Szczeiıkl A. Idiosyncrasy to pyrazolone drugs. Allergy 1981; 36(6): 381–384. PMID: 7316107